Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
LRMR Analyst Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
LRMR Stock 12 Month Forecast
Average Price Target
$20.17
▲(442.20% Upside)
| Highest Price Target$40.00 | Average Price Target$20.17 | Lowest Price Target$10.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Truist Financial
$18
Buy
383.87%
Upside
Reiterated
08/14/25
William Blair
―
Buy
―
Reiterated
08/14/25
Promising Data and Optimistic Outlook Drive Buy Rating for Larimar TherapeuticsWe expect the company to focus its presentation on levels of frataxin (FXN) expression in skin, which management feels optimistic will be viewed as a reasonably likely surrogate endpoint for accelerated approval of nomlabofusp based on FDA interactions through CDER’s START program. The prior Phase II clinical data of 50 mg nomlabofusp showed skin FXN levels approximating those of 50% of healthy volunteers (asymptomatic range), which we view as clearly exceeding the bar for success here, and further transcriptomic and lipidomic data gathered remain supportive. The agency has also been provided with nonclinical data of nomlabofusp showing human FXN expression in heart, skeletal muscle, and dorsal root ganglion that correlates with skin FXN expression levels in mouse models of FA and rats (De Toni F et al., 2025. AAPS).
Guggenheim
$26
Buy
598.92%
Upside
Reiterated
08/14/25
Citi
$14→$12
Buy
222.58%
Upside
Reiterated
08/14/25
JonesTrading
$12→$10
Buy
168.82%
Upside
Reiterated
08/04/25
Wedbush
$17→$15
Buy
303.23%
Upside
Reiterated
06/24/25
LifeSci Capital
$40
Buy
975.27%
Upside
Reiterated
06/23/25
TR | OpenAI - 4o
―
Hold
―
Reiterated
05/02/25
Citizens JMP
$21
Buy
464.52%
Upside
Reiterated
04/23/25
Robert W. Baird
$13→$10
Buy
168.82%
Upside
Reiterated
03/25/25
H.C. Wainwright
$15→$16
Buy
330.11%
Upside
Reiterated
03/25/25
Oppenheimer
$26
Buy
598.92%
Upside
Reiterated
12/17/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Truist Financial
$18
Buy
383.87%
Upside
Reiterated
08/14/25
William Blair
―
Buy
―
Reiterated
08/14/25
Promising Data and Optimistic Outlook Drive Buy Rating for Larimar TherapeuticsWe expect the company to focus its presentation on levels of frataxin (FXN) expression in skin, which management feels optimistic will be viewed as a reasonably likely surrogate endpoint for accelerated approval of nomlabofusp based on FDA interactions through CDER’s START program. The prior Phase II clinical data of 50 mg nomlabofusp showed skin FXN levels approximating those of 50% of healthy volunteers (asymptomatic range), which we view as clearly exceeding the bar for success here, and further transcriptomic and lipidomic data gathered remain supportive. The agency has also been provided with nonclinical data of nomlabofusp showing human FXN expression in heart, skeletal muscle, and dorsal root ganglion that correlates with skin FXN expression levels in mouse models of FA and rats (De Toni F et al., 2025. AAPS).
Guggenheim
$26
Buy
598.92%
Upside
Reiterated
08/14/25
Citi
$14→$12
Buy
222.58%
Upside
Reiterated
08/14/25
JonesTrading
$12→$10
Buy
168.82%
Upside
Reiterated
08/04/25
Wedbush
$17→$15
Buy
303.23%
Upside
Reiterated
06/24/25
LifeSci Capital
$40
Buy
975.27%
Upside
Reiterated
06/23/25
TR | OpenAI - 4o
―
Hold
―
Reiterated
05/02/25
Citizens JMP
$21
Buy
464.52%
Upside
Reiterated
04/23/25
Robert W. Baird
$13→$10
Buy
168.82%
Upside
Reiterated
03/25/25
H.C. Wainwright
$15→$16
Buy
330.11%
Upside
Reiterated
03/25/25
Oppenheimer
$26
Buy
598.92%
Upside
Reiterated
12/17/24
Best Analysts Covering Larimar Therapeutics
1 Month
xxx
Success Rate
6/9 ratings generated profit
Average Return
+4.82%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +4.82% per trade.
3 Months
xxx
Success Rate
5/9 ratings generated profit
Average Return
+38.34%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +38.34% per trade.
1 Year
Success Rate
16/24 ratings generated profit
Average Return
+32.01%
reiterated a buy rating 4 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +32.01% per trade.
2 Years
xxx
Success Rate
5/9 ratings generated profit
Average Return
+1.17%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of +1.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
LRMR Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
12
11
10
7
8
Buy
4
6
5
5
3
Hold
0
2
2
2
0
Sell
4
4
3
0
0
Strong Sell
0
0
0
0
0
total
20
23
20
14
11
Each month's total comprises the sum of three months' worth of ratings.
LRMR Financial Forecast
LRMR Stock Forecast FAQ
What is LRMR’s average 12-month price target, according to analysts?
Based on analyst ratings, Larimar Therapeutics, Inc.’s 12-month average price target is 20.17.
What is LRMR’s upside potential, based on the analysts’ average price target?
Larimar Therapeutics, Inc. has 442.20% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is LRMR a Buy, Sell or Hold?
Larimar Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is Larimar Therapeutics, Inc.’s price target?
The average price target for Larimar Therapeutics, Inc. is 20.17. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $10.00. The average price target represents 442.20% Increase from the current price of $3.72.
The highest analyst price target is $40.00 ,the lowest forecast is $10.00. The average price target represents 442.20% Increase from the current price of $3.72.
What do analysts say about Larimar Therapeutics, Inc.?
Larimar Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of LRMR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.